CureMatch Sponsors 14th Moores Cancer Center Industry/Academia Translational Oncology Symposium
CureMatch is proud to be one of the sponsors of this year’s 14th Moores Cancer Center Industry/Academia Translational Oncology Symposium which will be held on Thursday, February 22, 2018 (8am-6pm) at the Moores Cancer Center, located at 3855 Health Sciences Drive, La Jolla, CA 92093.
Duane Roth Award Lecture
Engineered T-Cells: The Sky’s the Limit
Carl June, MD
Richard W. Vague Professor Of Immunotherapy
Perelman School Of Medicine
University Of Pennsylvania
A New Model for Translational Research in the Nonprofit Sector
Peter Schultz, PhD
Chief Executive Officer
California Institute for Biomedical Research
ABOUT THIS SYMPOSIUM
Contemporary leaders of oncology are driven to redefine the notion of curative medicine by skillfully leveraging the power of collaboration to optimize everyone’s unique expertise and stretch research dollars in order to drive innovation. They are also changing clinical trial paradigms and emphasizing combination immunotherapy, new therapeutic modalities, and precision diagnosis. Already, as a result of these efforts, the oncology community can treat cancer patients and combat cancer at the molecular level.
The annual Industry/Academia Translational Oncology Symposium at Moores Cancer Center, now celebrating its 14th year, was created to support multi-modality collaborations and foster new partnerships in order to speed new therapies to patients. Each year the Symposium’s esteemed presenters from around the world, including clinicians, researchers, and top decision makers from industry and academia, attest to just how necessary it was for them to surmount multiple obstacles, in and out of the lab, in order to achieve success and help patients. The forum provides a platform for oncology innovators to highlight their interdisciplinary approach, as opposed to discussion on a specific type of cancer. Case study presentations showcase successful efforts, the challenges that they encountered, and the lessons they have learned from the process.
CureMatch, Inc. is a San Diego-based digital precision oncology company focused on personalized medicine and combination therapy. CureMatch Reports guide oncologists with actionable intelligence to customize treatment for each individual patient based on each specific molecular tumor profile. Precision medicine is considered by many to be the future of cancer treatment as combination therapy has been used effectively in the treatment of other diseases, such as HIV/AIDS. The CureMatch technology has expert foundation in supercomputing, oncology, genetics, proteomics, biochemistry, and cell biology. For more information, visit www.curematch.com.